{"id":2900,"date":"2026-11-11T22:42:53","date_gmt":"2026-11-11T14:42:53","guid":{"rendered":"http:\/\/www.puriactives.com\/en\/?p=2900"},"modified":"2026-11-11T22:42:53","modified_gmt":"2026-11-11T14:42:53","slug":"puriactives-%e7%94%9f%e7%89%a9%e6%99%ba%e9%80%a0%e8%a7%86%e9%bb%84%e9%86%9b","status":"publish","type":"post","link":"http:\/\/www.puriactives.com\/en\/?p=2900","title":{"rendered":"PuriActives\u00ae \u751f\u7269\u667a\u9020\u89c6\u9ec4\u919b"},"content":{"rendered":"<section lang=\"en\" data-pm-slice=\"4 4 [&quot;node&quot;,{&quot;tagName&quot;:&quot;main&quot;,&quot;attributes&quot;:{&quot;style&quot;:&quot;color: rgb(41, 70, 87);font-family: \\&quot;Microsoft YaHei\\&quot;, Arial, sans-serif;font-size: 16px;font-style: normal;font-variant-ligatures: normal;font-variant-caps: normal;font-weight: 400;letter-spacing: normal;orphans: 2;text-align: start;text-indent: 0px;text-transform: none;widows: 2;word-spacing: 0px;-webkit-text-stroke-width: 0px;white-space: normal;text-decoration-thickness: initial;text-decoration-style: initial;text-decoration-color: initial;line-height: 1.8;overflow-wrap: anywhere;&quot;},&quot;namespaceURI&quot;:&quot;http:\/\/www.w3.org\/1999\/xhtml&quot;}]\">\n<section>Active ingredient science \/ 2026<\/p>\n<h1>PuriActives\u00ae BioRetinal<\/h1>\n<p>BioRetinal \/ INCI: RETINAL<\/p>\n<section>Biotechnologically produced retinaldehyde: one metabolic step from retinoic acid<\/p>\n<\/section>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2901\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/01_\u7b2c01\u8282_\u539f\u59cb\u56fe\u7247-300x300.png\" alt=\"\" width=\"300\" height=\"300\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/01_\u7b2c01\u8282_\u539f\u59cb\u56fe\u7247-300x300.png 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/01_\u7b2c01\u8282_\u539f\u59cb\u56fe\u7247-150x150.png 150w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/01_\u7b2c01\u8282_\u539f\u59cb\u56fe\u7247.png 600w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<h3>Retinaldehyde<\/h3>\n<p>C\u2082\u2080H\u2082\u2088O \u00b7 284.4 g\/mol; the direct precursor of retinoic acid<\/p>\n<p>Scientific and technical product information: skin, scalp, and formulation<\/p>\n<p>Chemical structure source: PubChem CID 638015<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Product positioning<\/p>\n<h2>A defined retinoid identity for formulation innovation<\/h2>\n<p>PuriActives\u00ae BioRetinal combines biotechnological production with published research on topical retinaldehyde.<\/p>\n<section>\n<h3>01<\/h3>\n<h3>Product identity<\/h3>\n<p>PuriActives\u00ae BioRetinal<\/p>\n<p>One enzymatic step to retinoic acid<\/p>\n<p>INCI: Retinal \u00b7 C\u2082\u2080H\u2082\u2088O \u00b7 284.4 g\/mol<\/p>\n<\/section>\n<p>Retinaldehyde is immediately upstream of retinoic acid in cutaneous vitamin A metabolism, with a defined retinoid identity and direct topical research.<\/p>\n<p>[16] PubChem, Retinal CID 638015 \u00b7 [1] Zasada &amp; Budzisz, 2019<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Evidence framework<\/p>\n<h2>One molecule connects complementary lines of research<\/h2>\n<p>Direct retinaldehyde studies underpin the skin care evidence; related studies inform delivery and follicle biology.<\/p>\n<h3>Direct retinaldehyde evidence<\/h3>\n<h3>Topical retinaldehyde studies<\/h3>\n<p>Human studies assess wrinkles, texture, hydration, pigmentation, and tolerability. In vitro and human microbiology studies also inform blemish-prone skin care.<\/p>\n<h3>Related research<\/h3>\n<h3>Mechanistic and application research<\/h3>\n<p>RA\/tretinoin studies help explain follicular responses; PRN and RSC studies explore stabilization and delivery.<\/p>\n<p>Human studies: 0.05% and 0.1% topical formulas. In vitro studies: Propionibacterium acnes susceptibility. Delivery studies: niosomes and proretinal systems.<\/p>\n<p>Every result applies to its tested retinoid, carrier, model, and regimen.<\/p>\n<p>[3] Mukherjee et al., 2006 \u00b7 [12] Everts, 2012<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Scientific basis<\/p>\n<h2>Retinaldehyde is one enzymatic step from an active retinoid ligand<\/h2>\n<p>Cutaneous metabolism connects precursor identity with RAR\/RXR-mediated gene transcription.<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2917\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/17_\u7b2c04\u8282_\u4ee3\u8c22\u901a\u8def\u793a\u610f\u56fe_\u82f1\u6587\u7248-300x90.png\" alt=\"\" width=\"300\" height=\"90\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/17_\u7b2c04\u8282_\u4ee3\u8c22\u901a\u8def\u793a\u610f\u56fe_\u82f1\u6587\u7248-300x90.png 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/17_\u7b2c04\u8282_\u4ee3\u8c22\u901a\u8def\u793a\u610f\u56fe_\u82f1\u6587\u7248-1024x307.png 1024w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/17_\u7b2c04\u8282_\u4ee3\u8c22\u901a\u8def\u793a\u610f\u56fe_\u82f1\u6587\u7248-768x230.png 768w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/17_\u7b2c04\u8282_\u4ee3\u8c22\u901a\u8def\u793a\u610f\u56fe_\u82f1\u6587\u7248.png 1200w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<h3>Preclinical validation<\/h3>\n<p>Topical 0.05% retinaldehyde increased tissue RA in mouse tail skin and produced retinoid biological responses. [2]<\/p>\n<p>This metabolic position distinguishes retinaldehyde from retinol and retinoic acid. It does not justify exchanging efficacy conclusions or claiming a marketing potency multiplier.<\/p>\n<p>[1] Zasada &amp; Budzisz, 2019 \u00b7 [2] Didierjean et al., 1996<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Scientific basis<\/p>\n<h2>From nuclear signaling to measurable skin outcomes<\/h2>\n<p>Mechanistic research provides biological context; human studies assess efficacy.<\/p>\n<h3>Mechanistic context<\/h3>\n<section>RAR \/ RXR activation<\/p>\n<p>\u2193<\/p>\n<p>Keratinocyte differentiation and epidermal renewal<\/p>\n<p>\u2193<\/p>\n<p>Extracellular matrix homeostasis<\/p>\n<\/section>\n<p>Mechanistic value requires validation in a defined formula using appropriate measurements.<\/p>\n<p>[1] Zasada &amp; Budzisz, 2019 \u00b7 [3] Mukherjee et al., 2006<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Skin evidence<\/p>\n<h2>Topical retinaldehyde research spans more than two decades<\/h2>\n<p>Different study designs and formulas provide multidimensional evidence for skin care development.<\/p>\n<section>\n<h3>1998<\/h3>\n<p>0.05% RAL, RA, and vehicle comparison<\/p>\n<p>Profilometric assessment of wrinkles and roughness; follow-up to 44 weeks [4]<\/p>\n<\/section>\n<section>\n<h3>1999<\/h3>\n<p>0.05% RAL, 2 weeks<\/p>\n<p>Significant reduction in viable P. acnes [5]<\/p>\n<\/section>\n<section>\n<h3>2018<\/h3>\n<p>40 women, 3 months<\/p>\n<p>Texture, TEWL, hydration, and melanin index [6]<\/p>\n<\/section>\n<section>\n<h3>2024<\/h3>\n<p>32 women, 8 weeks<\/p>\n<p>0.1% retinaldehyde combination serum, 3 nights per week [8]<\/p>\n<\/section>\n<section>\n<h3>2025<\/h3>\n<p>27 participants, 6 weeks<\/p>\n<p>Anhydrous 0.1% retinaldehyde combination concentrate [9]<\/p>\n<\/section>\n<section>\n<h3>2026<\/h3>\n<p>56 women, 24 weeks<\/p>\n<p>Blinded split-face study of two RAL formulas [10]<\/p>\n<\/section>\n<p>[4] Creidi 1998 \u00b7 [6] Kwon 2018 \u00b7 [9] \u00c5kerstr\u00f6m 2025 \u00b7 [10] Deda 2026<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Skin evidence \/ Wrinkles<\/p>\n<h2>Different retinaldehyde formulas show visible wrinkle improvement<\/h2>\n<p>Instrumental studies link short-term imaging with longer-term wrinkle profiling.<\/p>\n<section>\u221214%<\/p>\n<p>Fine-line improvement at week 6<\/p>\n<p>Cohort median; p&lt;0.0001 [9]<\/p>\n<\/section>\n<h3>12-week split-face study<\/h3>\n<p>Length \u221271.1%; area \u221279.9%; volume \u221281.25%<\/p>\n<p>Median changes on the left forehead treated with the 0.1% RAL formula; respective p values: 0.018, 0.009, and 0.008. Different combination formulas were used on the two sides. [10]<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2903\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/03_\u7b2c07\u8282_\u539f\u59cb\u56fe\u7247-300x170.png\" alt=\"\" width=\"300\" height=\"170\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/03_\u7b2c07\u8282_\u539f\u59cb\u56fe\u7247-300x170.png 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/03_\u7b2c07\u8282_\u539f\u59cb\u56fe\u7247-1024x579.png 1024w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/03_\u7b2c07\u8282_\u539f\u59cb\u56fe\u7247-768x435.png 768w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/03_\u7b2c07\u8282_\u539f\u59cb\u56fe\u7247-1536x869.png 1536w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/03_\u7b2c07\u8282_\u539f\u59cb\u56fe\u7247-2048x1159.png 2048w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<p>Representative forehead region at baseline and week 6, with corresponding 3D analysis. Original Figure 9; anhydrous 0.1% retinaldehyde combination formula. [9]<\/p>\n<p>The image shows a representative region; its change is not the cohort median.<\/p>\n<p>[9] \u00c5kerstr\u00f6m et al., 2025, Figs 2 &amp; 9 \u00b7 [10] Deda et al., 2026<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Skin evidence \/ Firmness<\/p>\n<h2>Biomechanical and ultrasound measures expand the aging-skin evidence<\/h2>\n<p>In a split-face retinaldehyde study, Cutometer R2 increased in multiple facial regions after 24 weeks.<\/p>\n<section>24 weeks<\/p>\n<p>R2 \/ Overall elasticity<\/p>\n<\/section>\n<p>R2 increased significantly in forehead, cheek, and chin regions after 24 weeks (N=52).<\/p>\n<p>High-frequency ultrasound also showed increased dermal density in the assessed regions.<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2904\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/04_\u7b2c08\u8282_\u539f\u59cb\u56fe\u7247-300x185.png\" alt=\"\" width=\"300\" height=\"185\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/04_\u7b2c08\u8282_\u539f\u59cb\u56fe\u7247-300x185.png 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/04_\u7b2c08\u8282_\u539f\u59cb\u56fe\u7247-1024x632.png 1024w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/04_\u7b2c08\u8282_\u539f\u59cb\u56fe\u7247-768x474.png 768w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/04_\u7b2c08\u8282_\u539f\u59cb\u56fe\u7247.png 1200w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<p>Original Figure 12. T0 = baseline, T1 = week 24; different retinaldehyde combination formulas were used on the two sides. [10]<\/p>\n<p>[10] Deda et al., 2026, Fig 12<\/p>\n<p>Figure key: point = median; box = interquartile range; whiskers = minimum\u2013maximum; R\/L = right\/left.<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Skin evidence \/ Texture and barrier<\/p>\n<h2>Both study concentrations improve texture, hydration, and TEWL<\/h2>\n<p>A randomized double-blind study compared 0.1% and 0.05% retinaldehyde creams over three months.<\/p>\n<p>Change from baseline after 3 months (%)<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2918\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/18_\u7b2c09\u8282_\u7814\u7a76\u6570\u636e\u56fe\u8868_\u82f1\u6587\u7248-300x194.png\" alt=\"\" width=\"300\" height=\"194\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/18_\u7b2c09\u8282_\u7814\u7a76\u6570\u636e\u56fe\u8868_\u82f1\u6587\u7248-300x194.png 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/18_\u7b2c09\u8282_\u7814\u7a76\u6570\u636e\u56fe\u8868_\u82f1\u6587\u7248-1024x663.png 1024w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/18_\u7b2c09\u8282_\u7814\u7a76\u6570\u636e\u56fe\u8868_\u82f1\u6587\u7248-768x497.png 768w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/18_\u7b2c09\u8282_\u7814\u7a76\u6570\u636e\u56fe\u8868_\u82f1\u6587\u7248.png 1119w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<table>\n<tbody>\n<tr>\n<th>\n<section>Measure<\/section>\n<\/th>\n<th>\n<section>0.1% RAL<\/section>\n<\/th>\n<th>\n<section>0.05% RAL<\/section>\n<\/th>\n<\/tr>\n<tr>\n<td>\n<section>Texture improvement<\/section>\n<\/td>\n<td>\n<section>13.7%<\/section>\n<\/td>\n<td>\n<section>12.6%<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>TEWL reduction<\/section>\n<\/td>\n<td>\n<section>14.5%<\/section>\n<\/td>\n<td>\n<section>17.9%<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>Hydration increase<\/section>\n<\/td>\n<td>\n<section>10.2%<\/section>\n<\/td>\n<td>\n<section>6.0%<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Data from Kwon et al. [6]. Overall photoaging improvement was reported in 95% of both groups. There was no vehicle group, and between-concentration differences in the measures above were not significant.<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2926\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/06_\u7b2c09\u8282_\u539f\u59cb\u56fe\u7247-1-218x300.png\" alt=\"\" width=\"218\" height=\"300\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/06_\u7b2c09\u8282_\u539f\u59cb\u56fe\u7247-1-218x300.png 218w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/06_\u7b2c09\u8282_\u539f\u59cb\u56fe\u7247-1.png 694w\" sizes=\"(max-width: 218px) 100vw, 218px\" \/><\/section>\n<section>+12%<\/p>\n<p>Texture improvement at week 6 in a separate study of an anhydrous 0.1% retinaldehyde combination formula [9]<\/p>\n<\/section>\n<p>[6] Kwon et al., 2018 \u00b7 [9] \u00c5kerstr\u00f6m et al., 2025, Fig 4<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Skin evidence \/ Skin tone<\/p>\n<h2>Retinaldehyde formulas show measurable pigmentation improvement<\/h2>\n<p>Melanin index and imaging findings are complementary across three independent clinical studies.<\/p>\n<section>\u221212%<\/p>\n<p>Pigmentation improvement at week 6<\/p>\n<p>Cohort median; p&lt;0.0001 [9]<\/p>\n<\/section>\n<section>19%<\/p>\n<p>Improvement in visible pigmentation<\/p>\n<p>0.1% retinaldehyde + peptides\/ceramides\/lipids; 8 weeks [8]<\/p>\n<\/section>\n<section>6.5%<\/p>\n<p>Melanin index improvement after 3 months in the 0.1% RAL group [6]<\/p>\n<\/section>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2927\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/07_\u7b2c10\u8282_\u539f\u59cb\u56fe\u7247-1-300x177.png\" alt=\"\" width=\"300\" height=\"177\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/07_\u7b2c10\u8282_\u539f\u59cb\u56fe\u7247-1-300x177.png 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/07_\u7b2c10\u8282_\u539f\u59cb\u56fe\u7247-1-1024x603.png 1024w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/07_\u7b2c10\u8282_\u539f\u59cb\u56fe\u7247-1-768x452.png 768w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/07_\u7b2c10\u8282_\u539f\u59cb\u56fe\u7247-1-1536x904.png 1536w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/07_\u7b2c10\u8282_\u539f\u59cb\u56fe\u7247-1-2048x1205.png 2048w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<p>Representative pigmentation analysis at baseline and week 6. Original Figure 11; anhydrous 0.1% retinaldehyde combination formula. [9]<\/p>\n<p>The image shows a representative regional change, presented separately from the cohort median.<\/p>\n<p>[6] Kwon 2018 \u00b7 [8] Konisky 2024 \u00b7 [9] \u00c5kerstr\u00f6m 2025, Fig 11<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Skin evidence \/ Blemish-prone skin<\/p>\n<h2>Antibacterial and comedonal-care findings broaden potential applications<\/h2>\n<p>Direct P. acnes susceptibility testing complements a four-week study of retinaldehyde-loaded niosomes.<\/p>\n<h3>Minimum inhibitory concentration<\/h3>\n<table>\n<tbody>\n<tr>\n<th>\n<section>P. acnes strain<\/section>\n<\/th>\n<th>\n<section>RAL MIC<\/section>\n<\/th>\n<th>\n<section>RA MIC<\/section>\n<\/th>\n<\/tr>\n<tr>\n<td>\n<section>CIP179<\/section>\n<\/td>\n<td>\n<section>4 mg\/L<\/section>\n<\/td>\n<td>\n<section>&gt;128 mg\/L<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>CIP53119<\/section>\n<\/td>\n<td>\n<section>4 mg\/L<\/section>\n<\/td>\n<td>\n<section>&gt;128 mg\/L<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>CIP53117<\/section>\n<\/td>\n<td>\n<section>8 mg\/L<\/section>\n<\/td>\n<td>\n<section>&gt;128 mg\/L<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Daily 0.05% retinaldehyde significantly reduced viable P. acnes after 2 weeks; the vehicle did not. MIC is a microbiological measure, not a formulation use level. [5]<\/p>\n<h3>Sebum level (\u03bcg\/cm\u00b2)<\/h3>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2939\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/19_\u7b2c11\u8282_\u7814\u7a76\u6570\u636e\u56fe\u8868_\u82f1\u6587\u7248-1-300x170.png\" alt=\"\" width=\"300\" height=\"170\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/19_\u7b2c11\u8282_\u7814\u7a76\u6570\u636e\u56fe\u8868_\u82f1\u6587\u7248-1-300x170.png 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/19_\u7b2c11\u8282_\u7814\u7a76\u6570\u636e\u56fe\u8868_\u82f1\u6587\u7248-1-1024x582.png 1024w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/19_\u7b2c11\u8282_\u7814\u7a76\u6570\u636e\u56fe\u8868_\u82f1\u6587\u7248-1-768x436.png 768w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/19_\u7b2c11\u8282_\u7814\u7a76\u6570\u636e\u56fe\u8868_\u82f1\u6587\u7248-1.png 1111w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<table>\n<tbody>\n<tr>\n<th>\n<section>Time<\/section>\n<\/th>\n<th>\n<section>Sebum (\u03bcg\/cm\u00b2)<\/section>\n<\/th>\n<\/tr>\n<tr>\n<td>\n<section>Baseline<\/section>\n<\/td>\n<td>\n<section>327.95<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>Week 2<\/section>\n<\/td>\n<td>\n<section>282.6<\/section>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<section>Week 4<\/section>\n<\/td>\n<td>\n<section>250.65<\/section>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>0.05% retinaldehyde-loaded niosomal nanoemulsion, used daily for 4 weeks; n=23; p&lt;0.05. Findings apply to the niosomal system studied. [7]<\/p>\n<p>[5] Pech\u00e8re et al., 1999 \u00b7 [7] Kim et al., 2021<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Skin evidence \/ Tolerability<\/p>\n<h2>Favorable tolerability supports regular, sustained use<\/h2>\n<p>Evidence includes a 44-week controlled trial, recent clinical formulas, and instrumental erythema assessment.<\/p>\n<section>\n<h3>44 weeks<\/h3>\n<p>0.05% retinaldehyde was well tolerated; retinoic acid caused more local irritation and affected adherence. [4]<\/p>\n<\/section>\n<section>\n<h3>1 \/ 56<\/h3>\n<p>One participant reported skin irritation in the 24-week split-face retinaldehyde study. [10]<\/p>\n<\/section>\n<section>\n<h3>Patch testing<\/h3>\n<p>The tested 0.1% retinaldehyde combination serum showed no evidence of irritation or sensitization. [8]<\/p>\n<\/section>\n<section>\n<h3>p = 0.6664<\/h3>\n<p>Objective erythema did not change significantly at week 6 in the anhydrous 0.1% retinaldehyde study; mild adverse events were reported. [9]<\/p>\n<\/section>\n<p>Tolerability remains formula- and regimen-dependent. Several recent studies gradually increased application frequency.<\/p>\n<p>[4] Creidi 1998 \u00b7 [8] Konisky 2024 \u00b7 [9] \u00c5kerstr\u00f6m 2025 \u00b7 [10] Deda 2026<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Formulation science \/ Stability<\/p>\n<h2>The polyene structure makes stabilization a formulation priority<\/h2>\n<p>Covalent proretinal research quantifies the effects of light, oxygen, and carrier design.<\/p>\n<h3>40\u00b0C + sunlight + air<\/h3>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2929\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/09_\u7b2c13\u8282_\u539f\u59cb\u56fe\u7247-1-300x131.png\" alt=\"\" width=\"300\" height=\"131\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/09_\u7b2c13\u8282_\u539f\u59cb\u56fe\u7247-1-300x131.png 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/09_\u7b2c13\u8282_\u539f\u59cb\u56fe\u7247-1-1024x446.png 1024w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/09_\u7b2c13\u8282_\u539f\u59cb\u56fe\u7247-1-768x335.png 768w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/09_\u7b2c13\u8282_\u539f\u59cb\u56fe\u7247-1-1536x670.png 1536w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/09_\u7b2c13\u8282_\u539f\u59cb\u56fe\u7247-1.png 1782w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<section>1 vs 0.2<\/p>\n<p>Relative degradation rate during the first hour: free retinaldehyde versus proretinal nanoparticles (PRN).<\/p>\n<\/section>\n<h3>8 months \/ 25\u00b0C \/ protected from light<\/h3>\n<p>Free retinaldehyde: &gt;90% degradation<\/p>\n<p>PRN: &lt;10% retinoid loss<\/p>\n<p>Original Figure 3. PRN is a research chitosan\u2013retinaldehyde system. Free retinaldehyde was solubilized in ethanol. These findings are not BioRetinal stability specifications. [11]<\/p>\n<p>[11] Pisetpackdeekul et al., 2016, Fig 3<\/p>\n<p>Original axes: relative retinal amount (%) and time (minutes); PRN = proretinal nanoparticles.<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Formulation science \/ Delivery<\/p>\n<h2>Controlled release connects stability with skin performance<\/h2>\n<p>PRN illustrates sustained release from a covalent carrier at skin-relevant pH and changes in topical outcomes.<\/p>\n<h3>Release into artificial sebum<\/h3>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2930\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/10_\u7b2c14\u8282_\u539f\u59cb\u56fe\u7247-1-300x225.png\" alt=\"\" width=\"300\" height=\"225\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/10_\u7b2c14\u8282_\u539f\u59cb\u56fe\u7247-1-300x225.png 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/10_\u7b2c14\u8282_\u539f\u59cb\u56fe\u7247-1-1024x769.png 1024w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/10_\u7b2c14\u8282_\u539f\u59cb\u56fe\u7247-1-768x577.png 768w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/10_\u7b2c14\u8282_\u539f\u59cb\u56fe\u7247-1-1536x1153.png 1536w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/10_\u7b2c14\u8282_\u539f\u59cb\u56fe\u7247-1.png 1746w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<p>Original Figure 4. PRN was tested in artificial sebum at pH 5.0 and 4\u00b0C, protected from light, with sustained release measured for 8 hours. [11]<\/p>\n<h3>12-week split-face comparison<\/h3>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2931\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/11_\u7b2c14\u8282_\u539f\u59cb\u56fe\u7247-1-300x182.png\" alt=\"\" width=\"300\" height=\"182\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/11_\u7b2c14\u8282_\u539f\u59cb\u56fe\u7247-1-300x182.png 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/11_\u7b2c14\u8282_\u539f\u59cb\u56fe\u7247-1-1024x620.png 1024w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/11_\u7b2c14\u8282_\u539f\u59cb\u56fe\u7247-1-768x465.png 768w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/11_\u7b2c14\u8282_\u539f\u59cb\u56fe\u7247-1-1536x930.png 1536w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/11_\u7b2c14\u8282_\u539f\u59cb\u56fe\u7247-1-2048x1240.png 2048w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<p>Original Figure 7. PRN hydrogel versus 0.025% RA hydrogel, twice daily; n=30. Surface parameter \u221212.5% versus \u22127.1%; volume parameter \u22129.2% versus \u22125.1%. [11]<\/p>\n<p>[11] Pisetpackdeekul et al., 2016, Figs 4 &amp; 7<\/p>\n<p>Figure labels include retinal released (%), time (hours), surface\/volume, and texture parameters: energy, entropy, homogeneity, contrast, and variance.<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Formulation science \/ Development<\/p>\n<h2>Design around retention, compatibility, and delivery<\/h2>\n<p>The goal is to maintain retinaldehyde stability during manufacturing, storage, and consumer use.<\/p>\n<h3>01 \u00b7 Carrier architecture<\/h3>\n<p>Assess solubilization, aqueous exposure, and retinaldehyde distribution in the intended format.<\/p>\n<h3>02 \u00b7 Light and oxygen control<\/h3>\n<p>Assess formula and packaging exposure during processing, filling, and daily use.<\/p>\n<h3>03 \u00b7 Compatibility and processing<\/h3>\n<p>Screen antioxidants, chelators, polymers, and other excipients in the actual system.<\/p>\n<h3>04 \u00b7 Finished-formula validation<\/h3>\n<p>Track retinaldehyde content, degradation profile, appearance, and performance over time.<\/p>\n<section>\n<h3>Evidence to establish<\/h3>\n<p>Retinaldehyde content; degradation products; packaging compatibility; microbiological quality; scalp\/skin tolerability; application performance.<\/p>\n<\/section>\n<p>Potential formats: night serums, creams, and leave-on scalp concepts.<\/p>\n<p>[9] \u00c5kerstr\u00f6m et al., 2025 \u00b7 [11] Pisetpackdeekul et al., 2016<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Chapter 02 \/ Scalp and follicle science<\/p>\n<h2>A biologically grounded direction for scalp innovation<\/h2>\n<p>Retinoid metabolism participates in follicle biology. The opportunity requires rigorous translation, rather than borrowing hair-growth claims from other retinoids.<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2932\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/12_\u7b2c16\u8282_\u539f\u59cb\u56fe\u7247-1-300x231.jpg\" alt=\"\" width=\"300\" height=\"231\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/12_\u7b2c16\u8282_\u539f\u59cb\u56fe\u7247-1-300x231.jpg 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/12_\u7b2c16\u8282_\u539f\u59cb\u56fe\u7247-1-1024x787.jpg 1024w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/12_\u7b2c16\u8282_\u539f\u59cb\u56fe\u7247-1-768x590.jpg 768w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/12_\u7b2c16\u8282_\u539f\u59cb\u56fe\u7247-1.jpg 1050w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<p>Follicular structure across the hair cycle. Original Figure 2, Everts 2012. [12]<\/p>\n<p>Current evidence has not established hair-growth efficacy for BioRetinal.<\/p>\n<p>Hair-cycle labels: telogen, anagen, and catagen. Anatomical labels include sebaceous gland, bulge, hair fiber, inner root sheath (cuticle, Huxley\u2019s and Henle\u2019s layers), companion layer, outer root sheath, connective tissue sheath, secondary germ, dermal papilla, matrix, and bulb.<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Scalp and follicle science<\/p>\n<h2>The pilosebaceous unit has its own retinoid metabolism<\/h2>\n<p>Retinaldehyde lies between retinol and RA in follicular signaling.<\/p>\n<h3>Local metabolic sequence<\/h3>\n<section>Retinol \u2192 Retinaldehyde \u2192 RA<\/p>\n<p>DHRS9 ALDH1A1 \/ 2 \/ 3<\/p>\n<\/section>\n<h3>Regulated in space and time<\/h3>\n<p>RA-synthesizing enzymes, binding proteins, and receptors are distributed in follicular stem-cell-associated regions, with expression patterns changing across the hair cycle.<\/p>\n<p>The biological goal is homeostasis, rather than maximum retinoid exposure.<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2933\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/13_\u7b2c17\u8282_\u539f\u59cb\u56fe\u7247-1-243x300.jpg\" alt=\"\" width=\"243\" height=\"300\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/13_\u7b2c17\u8282_\u539f\u59cb\u56fe\u7247-1-243x300.jpg 243w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/13_\u7b2c17\u8282_\u539f\u59cb\u56fe\u7247-1-830x1024.jpg 830w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/13_\u7b2c17\u8282_\u539f\u59cb\u56fe\u7247-1-768x948.jpg 768w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/13_\u7b2c17\u8282_\u539f\u59cb\u56fe\u7247-1.jpg 851w\" sizes=\"(max-width: 243px) 100vw, 243px\" \/><\/section>\n<p>Original Figure 3. Components associated with follicular RA synthesis and reporter activity. [12]<\/p>\n<p>[12] Everts, 2012, Fig 3<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Scalp and follicle science \/ Related retinoids<\/p>\n<h2>RA\/tretinoin research informs hypotheses for follicle biology<\/h2>\n<p>Test compound: retinoic acid\/tretinoin. These results do not demonstrate retinaldehyde efficacy.<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2934\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/14_\u7b2c18\u8282_\u539f\u59cb\u56fe\u7247-1-288x300.jpg\" alt=\"\" width=\"288\" height=\"300\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/14_\u7b2c18\u8282_\u539f\u59cb\u56fe\u7247-1-288x300.jpg 288w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/14_\u7b2c18\u8282_\u539f\u59cb\u56fe\u7247-1.jpg 709w\" sizes=\"(max-width: 288px) 100vw, 288px\" \/><\/section>\n<p>Original Figure 3. Human AGA follicle organ culture: RA concentration series, morphology, hair-cycle stage, and proliferation measures. [13]<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2935\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/15_\u7b2c18\u8282_\u539f\u59cb\u56fe\u7247-1-300x231.jpg\" alt=\"\" width=\"300\" height=\"231\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/15_\u7b2c18\u8282_\u539f\u59cb\u56fe\u7247-1-300x231.jpg 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/15_\u7b2c18\u8282_\u539f\u59cb\u56fe\u7247-1.jpg 709w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<p>Original Figure 6. 0.025% tretinoin versus 5% minoxidil, twice daily; 30 participants per group. [13]<\/p>\n<p>[13] Wen et al., 2025, Figs 3 &amp; 6<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Scalp and follicle science \/ Dose response<\/p>\n<h2>Follicular responses depend on dose, model, and retinoid<\/h2>\n<p>Different RA study findings support direct retinaldehyde research rather than efficacy extrapolation.<\/p>\n<section>\n<h3>AGA follicle organ culture<\/h3>\n<p>10\u207b\u00b9\u00b2 M RA<\/p>\n<p>\u22481.3\u00d7 anagen proportion<\/p>\n<p>In Wen\u2019s study, hair-shaft elongation increased and anagen morphology was maintained versus DMSO. [13]<\/p>\n<\/section>\n<section>\n<h3>Human anagen VI scalp follicles<\/h3>\n<p>10\u207b\u2078 \/ 10\u207b\u00b9\u2070 M ATRA<\/p>\n<p>Approximately 80% catagen-like<\/p>\n<p>In Foitzik\u2019s study, approximately 30% of controls were catagen-like on day 6, and TGF-\u03b22 was upregulated with ATRA treatment. [14]<\/p>\n<\/section>\n<p>Next evidence step: directly assess retinaldehyde scalp tolerability, exposure, and follicular responses under defined formulation conditions.<\/p>\n<p>[13] Wen et al., 2025 \u00b7 [14] Foitzik et al., 2005<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Scalp and follicle science \/ Delivery research<\/p>\n<h2>Follicular targeting provides a specific formulation research model<\/h2>\n<p>An ex vivo porcine ear study tracked retinaldehyde release from a succinyl chitosan particle system.<\/p>\n<section><img loading=\"lazy\" class=\"alignnone size-medium wp-image-2940\" src=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/20_\u7b2c20\u8282_\u9012\u9001\u6a21\u578b\u793a\u610f\u56fe_\u82f1\u6587\u7248-1-300x117.png\" alt=\"\" width=\"300\" height=\"117\" srcset=\"http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/20_\u7b2c20\u8282_\u9012\u9001\u6a21\u578b\u793a\u610f\u56fe_\u82f1\u6587\u7248-1-300x117.png 300w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/20_\u7b2c20\u8282_\u9012\u9001\u6a21\u578b\u793a\u610f\u56fe_\u82f1\u6587\u7248-1-1024x400.png 1024w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/20_\u7b2c20\u8282_\u9012\u9001\u6a21\u578b\u793a\u610f\u56fe_\u82f1\u6587\u7248-1-768x300.png 768w, http:\/\/www.puriactives.com\/en\/wp-content\/uploads\/2026\/11\/20_\u7b2c20\u8282_\u9012\u9001\u6a21\u578b\u793a\u610f\u56fe_\u82f1\u6587\u7248-1.png 1100w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/section>\n<h3>01 \/ Particle design<\/h3>\n<p>RSC, 200\u2013300 nm + vitamin E<\/p>\n<p>Retinaldehyde was covalently linked to succinyl chitosan, combining an imine bond, a matrix, and antioxidant protection. [15]<\/p>\n<h3>02 \/ Ex vivo skin<\/h3>\n<p>Porcine ear skin; follicular penetration; confocal fluorescence imaging.<\/p>\n<h3>03 \/ Retinaldehyde release<\/h3>\n<p>Release into skin tissue<\/p>\n<p>The technical abstract reports that labeled particles entered follicles, followed by retinaldehyde release. [15]<\/p>\n<p>Ex vivo delivery evidence only; it does not demonstrate hair growth in humans.<\/p>\n<p>[15] Supmuang &amp; Wanichwecharungruang, TechConnect 2012<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Application development<\/p>\n<h2>Skin care concepts focused on measurable outcomes<\/h2>\n<p>Each concept links consumer goals with formulation and evidence priorities.<\/p>\n<section>\n<h3>01 \u00b7 Night-time renewal<\/h3>\n<p>Fine lines, firmness, and long-term skin quality<\/p>\n<p>Retinaldehyde retention; gradual-use regimen; imaging and Cutometer assessment.<\/p>\n<p>Serum or cream<\/p>\n<\/section>\n<section>\n<h3>02 \u00b7 Texture and skin tone<\/h3>\n<p>Smoothness, hydration, and visible pigmentation<\/p>\n<p>Barrier support; compatibility; Antera\/melanin index assessment.<\/p>\n<p>Targeted leave-on care<\/p>\n<\/section>\n<section>\n<h3>03 \u00b7 Blemish-prone skin care<\/h3>\n<p>Comedonal appearance and excess surface oil<\/p>\n<p>Delivery selection; sebum and lesion counts; tolerability.<\/p>\n<p>Lightweight leave-on formula<\/p>\n<\/section>\n<p>Development principle: validate the complete formula and regimen, beyond ingredient identity.<\/p>\n<p>[5] Pech\u00e8re 1999 \u00b7 [6] Kwon 2018 \u00b7 [9] \u00c5kerstr\u00f6m 2025 \u00b7 [10] Deda 2026<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Application development \/ Scalp<\/p>\n<h2>Translate follicle biology into a rigorous scalp development plan<\/h2>\n<p>A leave-on scalp serum is a research concept requiring defined formulation, tolerability, and efficacy milestones.<\/p>\n<h3>Concept \/ Leave-on scalp serum<\/h3>\n<h3>A lightweight, targeted scalp care format<\/h3>\n<p>Design for retinaldehyde retention, scalp comfort, and controlled deposition. Treat follicular delivery as a research variable rather than an established product feature.<\/p>\n<h3>Development stages<\/h3>\n<h3>01 Formulation<\/h3>\n<p>Retinaldehyde content, degradation profile, packaging compatibility, and deposition.<\/p>\n<h3>02 Tolerability<\/h3>\n<p>Scalp redness, itching, dryness, and participant comfort.<\/p>\n<h3>03 Exploratory efficacy<\/h3>\n<p>Phototrichogram assessment: hair count, density, diameter, and anagen proportion.<\/p>\n<h3>04 Translational validation<\/h3>\n<p>Define the comparator, regimen, and duration before developing claims.<\/p>\n<p>Initial goal: a stable, well-tolerated scalp formula for controlled efficacy research.<\/p>\n<p>[12] Everts 2012 \u00b7 [13] Wen 2025 \u00b7 [15] Supmuang 2012<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>Core value<\/p>\n<h2>BioRetinal connects ingredient identity with evidence-based development<\/h2>\n<p>Core value for international skin care and scalp innovation teams.<\/p>\n<h3>01 \u00b7 Biotechnological production<\/h3>\n<p>A defined product feature without unsupported process or certification claims.<\/p>\n<h3>02 \u00b7 Direct precursor of RA<\/h3>\n<p>Immediately upstream of retinoic acid, requiring one enzymatic conversion.<\/p>\n<h3>03 \u00b7 Extensive skin research<\/h3>\n<p>Human studies address wrinkles, texture, skin tone, blemish-prone skin care, and tolerability.<\/p>\n<h3>04 \u00b7 A rigorous innovation pathway<\/h3>\n<p>Formulation-first development, with scalp research grounded in follicle biology.<\/p>\n<p>[1] Zasada &amp; Budzisz 2019 \u00b7 [6] Kwon 2018 \u00b7 [10] Deda 2026 \u00b7 [12] Everts 2012<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>References<\/p>\n<h2>References \/ Mechanisms and skin evidence<\/h2>\n<p>Reference numbers match the in-text citations. Original figure numbers and study conditions appear in the adjacent captions.<\/p>\n<p>[1] Zasada M, Budzisz E. Retinoids: active molecules influencing skin structure formation in cosmetic and dermatological treatments. Adv Dermatol Allergol. 2019;36:392\u2013397. DOI: 10.5114\/ada.2019.87443.<\/p>\n<p>[2] Didierjean L, Carraux P, Grand D, et al. Topical retinaldehyde increases skin content of retinoic acid and exerts biologic activity in mouse skin. J Invest Dermatol. 1996;107:714\u2013719. DOI: 10.1111\/1523-1747.ep12365603. PMID: 8875955.<\/p>\n<p>[3] Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1:327\u2013348. DOI: 10.2147\/CIIA.2006.1.4.327.<\/p>\n<p>[4] Creidi P, Vienne MP, Ochonisky S, et al. Profilometric evaluation of photodamage after topical retinaldehyde and retinoic acid treatment. J Am Acad Dermatol. 1998;39:960\u2013965. DOI: 10.1016\/S0190-9622(98)70270-1. PMID: 9843009.<\/p>\n<p>[5] Pech\u00e8re M, Pech\u00e8re JC, Siegenthaler G, Germanier L, Saurat JH. Antibacterial activity of retinaldehyde against Propionibacterium acnes. Dermatology. 1999;199 Suppl 1:33\u201336. DOI: 10.1159\/000051375. PMID: 10473957.<\/p>\n<p>[6] Kwon HS, Lee JH, Kim GM, Bae JM. Efficacy and safety of retinaldehyde 0.1% and 0.05% creams used to treat photoaged skin: a randomized double-blind controlled trial. J Cosmet Dermatol. 2018;17:471\u2013476. DOI: 10.1111\/jocd.12551. PMID: 29663701.<\/p>\n<p>[7] Kim J, Kim J, Lee YI, Suk J, Lee D, Lee JH. A pilot study evaluating the efficacy and safety of retinaldehyde-loaded niosomes against mild-to-moderate acne. J Cosmet Dermatol. 2021;20:3586\u20133592. DOI: 10.1111\/jocd.14478. PMID: 34587353.<\/p>\n<p>[8] Konisky H, Bowe WP, Yang P, Kobets K. The Clinical Efficacy and Tolerability of a Novel Retinaldehyde Serum with Firming Peptides to Improve Skin Texture and Signs of Photoaging. J Drugs Dermatol. 2024;23:992\u2013997. DOI: 10.36849\/JDD.8058R1. PMID: 39496127.<\/p>\n<p>DOIs, PMIDs, and source links from the presentation are provided for verification.<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<section>References<\/p>\n<h2>References \/ Formulation, scalp, and chemical identity<\/h2>\n<p>Reference numbers match the in-text citations. Original figure numbers and study conditions appear in the adjacent captions.<\/p>\n<p>[9] \u00c5kerstr\u00f6m U, Gaudicheau C, Locret B, Gillbro JM. Efficacy and Safety of a Novel Anhydrous 0.1% Retinal-Based Concentrate with Hydrophilic Actives for Photoaged Skin: A Six-Week Prospective Study. Cosmetics. 2025;12:235. DOI: 10.3390\/cosmetics12060235.<\/p>\n<p>[10] Deda A, Odrzywo\u0142ek W, Lebiedowska A, et al. Comparative Evaluation of Topical Stabilized Retinaldehyde 0.1% vs. 0.05% on Skin Biophysical and Biomechanical Parameters. Skin Res Technol. 2026;32:e70326. DOI: 10.1111\/srt.70326. PMID: 41729119.<\/p>\n<p>[11] Pisetpackdeekul P, Supmuang P, Pan-In P, et al. Proretinal nanoparticles: stability, release, efficacy, and irritation. Int J Nanomedicine. 2016;11:3277\u20133286. DOI: 10.2147\/IJN.S111748. PMID: 27499622.<\/p>\n<p>[12] Everts HB. Endogenous retinoids in the hair follicle and sebaceous gland. Biochim Biophys Acta. 2012;1821:222\u2013229. DOI: 10.1016\/j.bbalip.2011.08.017. PMID: 21914489.<\/p>\n<p>[13] Wen L, Fan Z, Huang W, et al. Retinoic acid drives hair follicle stem cell activation via Wnt\/\u03b2-catenin signalling in androgenetic alopecia. J Eur Acad Dermatol Venereol. 2025;39:189\u2013201. DOI: 10.1111\/jdv.20000. PMID: 38629345.<\/p>\n<p>[14] Foitzik K, Spexard T, Nakamura M, Halsner U, Paus R. Towards dissecting the pathogenesis of retinoid-induced hair loss: all-trans retinoic acid induces premature hair follicle regression (catagen) by upregulation of TGF-\u03b22 in the dermal papilla. J Invest Dermatol. 2005;124:1119\u20131126.<\/p>\n<p>[15] Supmuang P, Wanichwecharungruang S. Triple protection delivery system for retinaldehyde: preparation, skin penetration and controlled release at the hair follicles. TechConnect Briefs. 2012;3:130\u2013133. ISBN: 978-1-4665-6276-9.<\/p>\n<p>[16] PubChem. Retinal, CID 638015. Molecular formula C\u2082\u2080H\u2082\u2088O; molecular weight 284.4 g\/mol; official 2D chemical structure. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/638015.<\/p>\n<p>PuriPharm Co. Ltd. \u00b7 service@puripharm.com \u00b7 www.puriactives.com<\/p>\n<p>DOIs, PMIDs, and source links from the presentation are provided for verification.<\/p>\n<p>PuriPharm Co. Ltd.<\/p>\n<\/section>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>Active ingredient science \/ 2026 PuriActives\u00ae BioRetina [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[25],"tags":[],"_links":{"self":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/2900"}],"collection":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2900"}],"version-history":[{"count":1,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/2900\/revisions"}],"predecessor-version":[{"id":2941,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/2900\/revisions\/2941"}],"wp:attachment":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2900"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2900"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}